Healios K.K. | Cash Flow

Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
179,916.00
476,503.00
958,128.00
3,426,741.00
1,771,550.00
Depreciation, Depletion & Amortization
11,797.00
119,327.00
128,068.00
142,938.00
74,934.00
Other Funds
-
50,000.00
5,919.00
4,774.00
34,359.00
Funds from Operations
202,175.00
486,852.00
760,575.00
3,250,451.00
2,274,192.00
Changes in Working Capital
72,976.00
329,775.00
593,403.00
532,227.00
512,008.00
Net Operating Cash Flow
275,151.00
157,077.00
167,172.00
3,782,678.00
1,762,184.00
Capital Expenditures
17,916.00
123,180.00
62,244.00
92,494.00
72,107.00
Sale of Fixed Assets & Businesses
-
-
-
-
1,300,000.00
Purchase/Sale of Investments
8,863.00
30,375.00
150,001.00
9,125.00
5,819.00
Net Investing Cash Flow
291,779.00
888,555.00
212,245.00
103,200.00
1,229,611.00
Issuance/Reduction of Debt, Net
3,000.00
-
-
2,500,000.00
129,000.00
Net Financing Cash Flow
2,985,010.00
78,725.00
7,654,551.00
2,532,014.00
11,733,687.00
Net Change in Cash
2,968,382.00
964,465.00
7,248,935.00
1,369,096.00
11,213,725.00
Free Cash Flow
257,235.00
271,826.00
226,208.00
3,872,663.00
1,833,791.00
Net Assets from Acquisitions
265,000.00
735,000.00
-
-
-
Change in Capital Stock
2,988,010.00
28,725.00
7,648,632.00
27,240.00
11,828,328.00
Exchange Rate Effect
-
2,442.00
26,199.00
15,232.00
12,611.00
Other Uses
-
-
-
1,580.00
4,100.00

About Healios

View Profile
Address
World Trade Center Building, 15/F
Tokyo Tokyo 105
Japan
Employees -
Website http://www.healios.co.jp
Updated 07/08/2019
Healios KK engages in the development and sale of ophthalmological surgery adjuvants. It aims to commercialize pharmaceutical hiPSC derived retinal pigment epithelium (RPE) cell transplantation for the treatment of age-related macular degeneration. The firm develops therapies for the regeneration of retinal function and to improve visual function in those affected with retinal degenerative diseases.